Dashboard
Manage Tickers

ABBVAbbVie Inc.

NYSE abbvie.com


$ 162.42 $ 1.16 (0.72 %)    

Friday, 03-May-2024 10:23:08 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 433.54 $ 1.22 (0.28 %)
DIA $ 385.94 $ 3.97 (1.04 %)
SPY $ 509.33 $ -1.17 (-0.23 %)
TLT $ 89.46 $ -0.65 (-0.72 %)
GLD $ 211.54 $ -1.88 (-0.88 %)
$ 160.81
$ 161.26
$ 162.38 x 100
$ 0.00 x 0
$ 160.83 - $ 163.23
$ 125.85 - $ 181.20
5,904,251
na
285.12B
$ 0.64
$ 58.63
TBD
na
na ($ 0.04)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-20-2024 12-31-2023 10-K
2 11-06-2023 09-30-2023 10-Q
3 08-07-2023 06-30-2023 10-Q
4 05-05-2023 03-31-2023 10-Q
5 02-17-2023 12-31-2022 10-K
6 11-04-2022 09-30-2022 10-Q
7 08-04-2022 06-30-2022 10-Q
8 05-06-2022 03-31-2022 10-Q
9 02-18-2022 12-31-2021 10-K
10 11-02-2021 09-30-2021 10-Q
11 08-02-2021 06-30-2021 10-Q
12 05-07-2021 03-31-2021 10-Q
13 02-19-2021 12-31-2020 10-K
14 11-04-2020 09-30-2020 10-Q
15 08-04-2020 06-30-2020 10-Q
16 05-08-2020 03-31-2020 10-Q
17 02-21-2020 12-31-2019 10-K
18 11-06-2019 09-30-2019 10-Q
19 08-05-2019 06-30-2019 10-Q
20 05-03-2019 03-31-2019 10-Q
21 02-27-2019 12-31-2018 10-K
22 11-07-2018 09-30-2018 10-Q
23 08-07-2018 06-30-2018 10-Q
24 05-04-2018 03-31-2018 10-Q
25 02-16-2018 12-31-2017 10-K
26 11-07-2017 09-30-2017 10-Q
27 08-07-2017 06-30-2017 10-Q
28 05-05-2017 03-31-2017 10-Q
29 02-17-2017 12-31-2016 10-K
30 11-07-2016 09-30-2016 10-Q
31 08-05-2016 06-30-2016 10-Q
32 05-06-2016 03-31-2016 10-Q
33 02-19-2016 12-31-2015 10-K
34 11-06-2015 09-30-2015 10-Q
35 08-07-2015 06-30-2015 10-Q
36 05-08-2015 03-31-2015 10-Q
37 02-20-2015 12-31-2014 10-K
38 11-07-2014 09-30-2014 10-Q
39 08-07-2014 06-30-2014 10-Q
40 05-09-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

1000-invested-in-this-stock-10-years-ago-would-be-worth-3100-today
$1000 Invested In This Stock 10 Years Ago ...
05/02/2024 18:30:17

Core News & Articles
CNBC Halftime Report Final Trades: Amazon....
04/30/2024 17:01:00

barclays-maintains-overweight-on-abbvie-lowers-price-target-to-187
Barclays Maintains Overweight on AbbVie, L...
04/29/2024 15:26:59

Barclays analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and lowers the price target from $195 to $187.

peeling-back-the-layers-exploring-abbvie-through-analyst-insights
Peeling Back The Layers: Exploring AbbVie ...
04/29/2024 15:01:09

bmo-capital-maintains-outperform-on-abbvie-lowers-price-target-to-180
BMO Capital Maintains Outperform on AbbVie...
04/29/2024 14:09:17

BMO Capital analyst Evan David Seigerman maintains AbbVie (NYSE:ABBV) with a Outperform and lowers the price target from $19...

will-earnings-cheer-continue-to-buoy-markets-apple-amazon-pfizer-coinbase-lead-flurry-of-q1-reports-this-week
Will Earnings Cheer Continue To Buoy Marke...
04/29/2024 05:51:21

With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and...

arthritis-patients---cignas-evernorth-to-offer-humira-biosimilar-at-no-out-of-pocket-cost
Arthritis Patients - Cigna's Evernorth To ...
04/26/2024 18:41:57

Evernorth Health Services' initiative to offer Humira biosimilar with $0 out-of-pocket costs for patients. Save an average ...

tech-stocks-rebound-as-magnificent-7-roar-on-strong-earnings-energy-giants-tumble-whats-driving-markets-friday
Tech Stocks Rebound As Magnificent 7 Roar ...
04/26/2024 17:45:42

Strong earnings reports from Alphabet Inc. (NASDAQ:GOOGL) and Microsoft Corp. (NASDAQ:MSFT) have restored positive sentiment in...

ex-humira-growth-platform-drives-abbvies-q1-performance-drugmaker-lifts-annual-profit-outlook
Ex-Humira Growth Platform Drives AbbVie's ...
04/26/2024 13:54:00

AbbVie impresses with Q1 results: EPS beats at $2.31 (-6.1% Y/Y), net revenue exceeds at $12.31 billion (+0.7%). Notable: Immun...

abbvie-shares-are-trading-higher-after-the-company-reported-better-than-expected-q1-financial-results-and-raised-its-fy24-adjusted-eps-guidance-above-estimates
AbbVie shares are trading higher after the...
04/26/2024 11:43:06

abbvie-is-raising-its-2024-adjusted-eps-guidance-from-1097-1117-to-1113-1133-which-includes-an-unfavorable-impact-of-008-per-share-related-to-acquired-iprd-and-milestones-expense-versus-consensus-of-1112
AbbVie Is Raising Its 2024 Adjusted EPS Gu...
04/26/2024 11:38:57

abbvie-q1-2024-adj-eps-231-beats-223-estimate-sales-12310b-beat-11923b-estimate
AbbVie Q1 2024 Adj EPS $2.31 Beats $2.23 E...
04/26/2024 11:36:58

AbbVie (NYSE:ABBV) reported quarterly earnings of $2.31 per share which beat the analyst consensus estimate of $2.23 by 3.59 pe...

wall-street-futures-ride-high-on-microsoft-alphabet-cheer-but-will-inflation-data-burst-the-bubble-why-this-analyst-thinks-bull-run-isnt-over-yet
Wall Street Futures Ride High On Microsoft...
04/26/2024 10:48:12

Tech earnings could come to the market’s rescue as traders remain jittery about the outcome of key inflation data due on Friday.

abbvies-dermatitis-drug-shown-superior-to-sanofiregenerons-dupixent-in-head-to-head-study
AbbVie's Dermatitis Drug Shown 'Superior' ...
04/25/2024 17:58:29

AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficac...

abbvie-new-data-show-rinvoq-demonstrated-superiority-versus-dupixent-across-primary-and-all-secondary-endpoints-in-an-open-label-head-to-head-atopic-dermatitis-study-achieved-both-a-90-or-greater-reduction-in-eczema-area-and-severity-index-and-a-worst-pruritus-numerical-rating-scale-of-0-or-1-at-week-16
AbbVie New Data Show RINVOQ Demonstrated S...
04/25/2024 12:09:22

Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin cl...

abbvies-options-frenzy-what-you-need-to-know
AbbVie's Options Frenzy: What You Need to ...
04/23/2024 18:45:50

can-magnificent-7-help-script-market-turnaround-earnings-pick-up-pace-with-microsoft-meta-alphabet-and-tesla-expected-this-week
Can Magnificent 7 Help Script Market Turna...
04/21/2024 21:45:15

Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.

soon-to-be-acquired-cerevel-therapeutics-reveals-high-level-data-from-late-stage-parkinsons-disease-study
Soon To Be Acquired Cerevel Therapeutics R...
04/18/2024 17:44:09

Discover toplines results of Cerevel Therapeutics' Phase 3 TEMPO-3 trial for tavapadon in Parkinson's disease treatment...

abbvie-announces-phase-3-select-gca-study-of-upadacitinib-results-in-patients-with-giant-cell-arteritis-in-combination-with-a-26-week-steroid-taper-regimen-achieved-its-primary-endpoint-of-sustained-remission-key-secondary-endpoints-were-also-met
AbbVie Announces Phase 3 SELECT-GCA Study ...
04/18/2024 12:32:50

−     Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated ...

is-your-botox-real-or-fake-counterfeit-boxes-circulate-for-widely-used-antiwrinkle-treatment-cdc-and-fda-investigate-harmful-reactions
Is Your Botox Real Or Fake? Counterfeit Bo...
04/17/2024 18:42:23

Be cautious of counterfeit Botox for cosmetic use. FDA warns of adverse reactions in multiple states. Symptoms include vision i...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION